85 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
ADUS Addus HomeCare Corporation $68.95 $806.53M Downtrend
Article Searches
TrovaGene (TROV) Reports Wider-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253024/trovagene-trov-reports-wider-than-expected-loss-in-q4?cid=CS-ZC-FT-253024 Mar 16, 2017 - TrovaGene Inc. (TROV) reported loss of 31 cents per share in the fourth quarter of 2016, 2 cents wider than the Zacks Consensus Estimate.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253014/catalyst-cprx-reports-narrower-than-expected-loss-in-q4?cid=CS-ZC-FT-253014 Mar 16, 2017 - Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Jazz Initiates Phase III Study for Narcolepsy Candidate http://www.zacks.com/stock/news/253080/jazz-initiates-phase-iii-study-for-narcolepsy-candidate?cid=CS-ZC-FT-253080 Mar 16, 2017 - Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III http://www.zacks.com/stock/news/252915/astrazenecas-cancer-drug-lynparza-positive-in-phase-iii?cid=CS-ZC-FT-252915 Mar 15, 2017 - AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up http://www.zacks.com/stock/news/252900/arena-pharmaceuticals-arna-posts-q4-earnings-revenues-up?cid=CS-ZC-FT-252900 Mar 15, 2017 - Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.
Cogentix (CGNT) Q4 Earnings and Revenues Miss Estimates http://www.zacks.com/stock/news/252426/cogentix-cgnt-q4-earnings-and-revenues-miss-estimates?cid=CS-ZC-FT-252426 Mar 10, 2017 - Cogentix Medical, Inc. (CGNT) reported adjusted loss of 14 cents per share in the fourth quarter of 2016.
Notable earnings after Monday’s close http://seekingalpha.com/news/3248695-notable-earnings-monday-s-close?source=feed_news_all Mar 05, 2017 - ADUS, AKBA, ALOG, ASNA, ATSG, AVD, BDE, CASY, DAVE, DCO, KFY, KTWO, MEET, MNTX, PLOW, PRTS, THO, WMC
Addus HomeCare's (ADUS) CEO Dirk Allison on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3994632-addus-homecares-adus-ceo-dirk-allison-q2-2016-results-earnings-call-transcript?source=feed_sector_healthcare Aug 02, 2016 - Addus HomeCare Corporation (NASDAQ:ADUS) Q2 2016 Results Earnings Conference Call August 2, 2016 9:00 a.m. ET Executives Dirk Allison - President and Chief Executive Officer Brian Poff - Executive Vic
Notable earnings after Monday’s close http://seekingalpha.com/news/3198081-notable-earnings-monday-s-close?source=feed_news_all Jul 31, 2016 - [[ADUS]], [[AEGN]], [[AEIS]], [[AMKR]], [[APU]], [[ARE]], [[ATW]], [[BDE]], [[BLKB]], [[CEMP]], [[CGNX]], [[CHGG]], [[CKEC]], [[CONE]], [[CUTR]], [[DAC]],
Peek Into Aug 1 Healthcare Stocks' Q2 Earnings: ADUS, THC http://www.zacks.com/stock/news/225741/peek-into-aug-1-healthcare-stocks-q2-earnings-adus-thc?cid=CS-ZC-FT-225741 Jul 29, 2016 - Here, we take a sneak peek at two healthcare stocks scheduled to report their second-quarter figures on Aug 1.

Pages: 1...3456789

<<<Page 8